Document Classification

Section Type: RESULTS

Text: Slightly fewer patients in the olmesartan group than in the placebo group had nonfatal cardiovascular events -- 81 of 2232 patients (3. 6 %) as compared with 91 of 2215 patients (4. 1 %) (P = 0. 37) -- but a greater number had fatal cardiovascular events -- 15 patients (0. 7 %) as compared with 3 patients (0. 1 %) (P = 0. 01), a difference that was attributable in part to a higher rate of death from cardiovascular causes in the olmesartan group than in the placebo group among patients with preexisting coronary heart disease (11 of 564 patients [2. 0 %] vs. 1 of 540 [0. 2 %], P = 0. 02).